Kornimate/medical-research-clean huggingface dataset:
full-dose atorvastatin after acute coronary syndrome (acs) in non-revascularisable coronary artery disease

Conditions: Acute Coronary Syndrome; Coronary Artery Disease

Summary: this study was designed to test the hypothesis that the addition of full-dose atorvastatin (80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after non-st-elevation acute myocardial infarction (nste-ami) in patients with severe and diffuse coronary artery disease (cad) not amenable to any form of mechanical revascularisation.


Eligibility criteria:
inclusion criteria: * non-st-segment elevation acute myocardial infarction. * coronary angiography within 48 hours from admission. * angiographic evidence of severe and diffuse coronary artery disease,not amenable to conventional direct revascularisation techniques by coronary artery bypass graft (cabg) or percutaneous coronary intervention (pci). exclusion criteria: * st-segment elevation acute myocardial infarction, * clinical history of heart failure * left ventricular ejection fraction \<35%, * any form of severe valvular dysfunction, * previous implantation or indication to implant a cardioverter-defibrillator during the index admission, * any increase in liver enzymes, * history of any liver or muscle disease, * renal failure with serum creatinine \>2.5 mg/dl (221 mmol/l), * need for continued use of intravenous medications to relieve anginal symptoms, * presence of any major comorbidity with life expectancy \<24 months.

Keywords: atorvastatin acute coronary syndrome advanced coronary artery disease
effect mobility during induction of labor on time to delivery. a randomized controlled trial

Conditions: Labor Onset and Length Abnormalities

Summary: this is a andomized controlled trial the evaluates the effect of enhanced mobility, controlled via electronic pedometers, during induction of labor by extra amniotic balloon on time to delivery.


Eligibility criteria:
inclusion criteria: * pregnant women * low risk pregnancies * singlelton * vertex position * undergoing labor induction with extra amniotic catheter * no contraindication for enhanced mobility exclusion criteria: * medical recommendation for limited mobility * status post cesarean delivery * twin pregnancy * premature rupture of membranes * severe preeclampsia * maternal comorbidity
a study of factors influencing recurrence after thermal ablation of papillary thyroid carcinoma

Conditions: Papillary Thyroid Carcinoma; Thermal Ablation

Summary: a prospective cohort of papillary thyroid carcinoma(ptc), patients who received thermal ablation in our hospital since february 2023 was established as the study object. preoperative and postoperative demographic data, ultrasonography, other relevant laboratory tests, and thyroid disease-related scales such as fatigue, depression, and stress were collected. the influencing factors of ptc recurrence were analyzed.


Eligibility criteria:
inclusion criteria: ①≥18 years old; ② obtain informed consent; ③ ultrasonography showed that malignant nodules were single, the maximum diameter of nodules was ≤1cm and the distance from the capsule was ≥2mm. ④ no lymph node metastasis or other extra-glandular metastasis in the neck; ⑤ ptc was confirmed by fine needle puncture pathology; ⑥ patients who do not meet article 3, who still strongly request thermal ablation while fully informing the patient of the risk of recurrence, and who have been clinically assessed to be technically capable of thermal ablation exclusion criteria:① pregnant or lactating patients; ② patients with other malignant tumors and not suitable for ablation by clinical evaluation; ③ patients who cannot tolerate surgery; ④ patients with cognitive impairment and other conditions who cannot accurately fill in thyroid-related questionnaires.

Keywords: papillary thyroid carcinoma cohort thermal ablation recurrence
safety study of the selective inhibitor of nuclear export (sine) kpt-330 in patients with advanced hematological cancer

Conditions: Hematological Malignancies

Summary: the purpose of this research study is to find out more information relating to the highest dose of kcp-330 that can be given safely and side effects it may cause, to examine how the body affects kcp-330 concentrations in the blood (pharmacokinetics or pk), to examine the effects of kcp-330 on the body (pharmacodynamics or pdn) and to obtain information on its effectiveness in treating cancer.


Eligibility criteria:
inclusion criteria 1. malignancies that are refractory to or intolerant of established therapy known to provide clinical benefit. patients must not be candidates for anti-tumor regimes known to provide clinical benefit. 2. all patients must have evidence of progressive disease on study entry. previously untreated patients who are not chemotherapy candidates on arm 2 may have advanced disease (without clear progression). there is no upper limit on the number of prior treatments provided that all inclusion criteria are met, and exclusion criteria are not met. exclusion criteria 1. radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤2 weeks prior to cycle 1 day 1 and mitomycin c and radioimmunotherapy 6 weeks prior to cycle 1 day 1. 2. patients with active graft versus host disease after allogeneic stem cell transplantation. at least 3 months must have elapsed since completion of allogeneic stem cell transplantation except for patients with aml, where at least 2 months must have elapsed; 3. known active hepatitis a, b, or c infection; or known to be positive for hcv rna or hbsag (hbv surface antigen); 4. patients with active cns malignancy. asymptomatic small lesions are not considered active. treated lesions may be considered inactive if they are stable for at least 3 months. patient with malignant cells in their cerebrospinal fluid (csf) without cns symptom may be included. 5. significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea. 6. grade ≥2 peripheral neuropathy at baseline (within 14 days prior to cycle 1 day 1). 7. macular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity. 8. in the opinion of the investigator, patients who are significantly below their ideal body weight.

Keywords: selinexor kpt-330 multiple myeloma non-hodgkin lymphoma chronic lymphocytic leukemia waldenström's macroglobulinemia peripheral t-cell lymphoma cutaneous t-cell lymphoma chronic myelocytic leukemia acute lymphoblastic leukemia
rehabilitation of reconstructed shoulder rotator cuff

Conditions: Full Thickness Rotator Cuff Tear

Summary: the aim of this study to define the optimal rehabilitation for clients with full thickness rotator cuff reconstruction, with two goals: 1. finding the optimal physical therapy dosage in enhancing post-operative outcomes of shoulder pain, shoulder joint range of motion, shoulder muscle strength, upper extremity function; and 2. finding the effect of aquatic physical therapy in enhancing the post-operative outcomes.

measurement devices: biodex: biodex system is a muscle strength testing and rehabilitation instrument used in the testing and rehabilitation services for shoulder, elbow, wrist, hip, knee and ankle. modes of operation for exercise and testing include isokinetic, passive, isometric, isotonic, and reactive eccentric. patients are tested for their muscle performance for the required number of repetitions in the required mode. the muscle performance is measured by calculating the average peak torque (in nm) and analyzed across the group of patients. goniometer: a manual devise used to measure joint range of motion. visual analogue scale: a scale with 0 to 10, with 0 being no pain, and 10 being severe pain. measurement procedure: all the subjects posted for surgery will be tested prior to and again 6 weeks following surgery for: shoulder pain is measured using a visual analog scale. shoulder range of motion is measured using a standard goniometer. shoulder muscle performances are measured using biodex.

Eligibility criteria:
inclusion criteria: * full thickness rotator cuff tear treated by arthroscopic or mini-open repair by a specialized upper extremity surgeons * mentally competent * able to read and write * able to return for follow-up * 18-65 years old exclusion criteria: * associated surgical procedures (concomitant fractures, capsular releases surgical decompression) * nerve injury * neurological conditions * irreparable massive rotator cuff tear, and * comorbid health problems that limit rehabilitation potential (rheumatoid arthritis, diabetes).

Keywords: shoulder rehabilitation rotator cuff tear physiotherapy aqua therapy therapy dosage adjunctive aquatic physical therapy
safety and tolerability of lactoferrin in very low birth weight infants

Conditions: Very Low Birth Weight Infants

Summary: to evaluate the safety and tolerability of three different lactoferrin doses in preterm infants

aim1: to evaluate the safety and tolerability of three different lactoferrin doses in preterm infants 1. lactoferrin related adverse events and serious adverse events 2. number of infants reaching full feeds while receiving lactoferrin (120 ml/kg/day) 3. episodes of not receiving enteral feedings for \> 24 hours once feeding is initiated aim 2: to evaluate lactoferrin absorption and excretion. 1. examine lactoferrin levels in saliva, urine, plasma and stool 2. examine lactoferrin levels in maternal and human donor milk. aim 3: to evaluate the effect of lactoferrin on the intestinal microbiome structure.

Eligibility criteria:
inclusion criteria: * \< 15 days of age and receiving enteral feedings * \< 1500 grams birth weight * \<37 weeks gestation exclusion criteria: * congenital bowel obstruction ( esophageal, duodenal, small bowel or anal atresias, hirschsprung disease, malrotation) * known necrotizing enterocolitis or bowel perforation

Keywords: lactoferrin very low birth weight infants preterm infants
folfiri versus docetaxel and cisplatin as a second-line chemotherapy after failure of first-line chemotherapy in advanced gastric cancer

Conditions: Inoperable Gastric Cancer

Summary: patients diagnosis with inoperable gastric cancers are treated with palliative chemotherapy. palliative chemotherapy had proven to be better overall survivals and quality of life in unresectable advanced gastric cancer. nccn guideline suggested two or three drug cytotoxic regimen as a first line therapy. but response rate of those regimens is about 50 percent. disappointingly most of cases are about to experience progression of disease. second line regimens of palliative chemotherapy are also have shown its efficacy and recommended within patients with better performance status. but there is still lack of evidences in gastric cancer patients second line chemotherapy. several phase ii trial those subjects are 2nd line palliative chemotherapy in gastric cancer had suggested that irinotecan, taxane, oxaliplatin, oral fluorouracil.investigator assessed whether cisplatin in combination with paclitaxel would increase response rate in patient previously treated for advanced gastric cancer compared with fofiri regimen.


Eligibility criteria:
inclusion criteria: 1. older than 19 years old and younger than 75 years old 2. pathologically confirmed gastric cancer 3. inoperable stage at diagnosis 4. experienced diseases progression in first line palliative chemotherapy 5. ecog performance status 0 or 1 6. adequate renal function (serum creatinine \< 1.5 mg/dl or calculated creatinine clearance ≥ 60 ml/min) 7. adequate liver function (total bilirubin \< 1.5 x the upper limits of normal (uln), ast and alt \<3 x unl, and alkaline phosphatases \< 3 x uln or \< 5 x uln in case of liver involvement) 8. adequate bm function (wbc ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl) 9. subjects who given written informed consent after being given a full description of the study exclusion criteria: 1. double primary cancer other than gastric cancer 2. history of palliative radiation therapy 3. pregnant or on breast feeding 4. neuropathy grade \> 3 5. active infection 6. symptomatic cardiopulmonary diseases 7. active hepatitis of liver cirrhosis 8. impaired renal function 9. impaired psychologic bone marrow function 10. psychologic disorder, severe neurologic disorder. 11. hypersensitivity to chemotherapeutic agent

Keywords: inoperable gastric cancer palliative chemotherapy
metabolic effects of non-thymidine analogue anti-hiv medications

Conditions: HIV Infections

Summary: the purpose of this study is to observe the effects of certain anti-hiv medications on mitochondrial activity and fat cell death. this study will enroll participants from another study, actg a5202, who are on treatment regimens that do not include zidovudine, stavudine, or other thymidine-containing anti-hiv medications.

the main objective of this study is to observe the effects of anti-hiv medication lacking thymidine on mitochondrial metabolism and adipocyte apoptosis (fat cell death). changes in mitochondrial metabolism and increases in adipocyte apoptosis are associated with lipoatrophy. lipoatrophy is a common condition characterized by loss of subcutaneous fat and can be caused by many anti-hiv medications. this study will examine the metabolic consequences of the use of thymidine analogue-sparing treatment regimens. this study will evaluate hiv infected patients who are enrolled in actg a5202, starting their first nucleoside reverse transcriptase inhibitor (nrti)-containing regimen. this regimen will include either tenofovir disoproxil fumarate/emtricitabine (tdf/ftc) or abacavir/lamivudine (abc/3tc), which are thymidine-sparing regimens. the changes in mitochondrial activity and fat cell death will be compared between participants taking thymidine-sparing regimens (tdf/ftc or abc/3tc) and thymidine-containing regimens. this study will last for 96 weeks, with two study visits occurring at entry and another visit at week 96. during each visit, a dual energy x-ray absorptiometry (dexa) scan and blood collection will occur, and a fat biopsy will be performed in the lower abdomen under local anesthetic.

Eligibility criteria:
inclusion criteria: * hiv-infected * enrolling in actg a5202 and its metabolic substudy actg a5224 exclusion criteria: * bleeding problems * cannot undergo fat biopsies * require aspirin anytime in the 7-day period prior to each biopsy

Keywords: mitochondria fat apoptosis lipoatrophy lipodystrophy thymidine treatment experienced
study to investigate safety, efficacy of an anti-ifnγ mab in children with primary haemophagocytic lymphohistiocytosis

Conditions: Primary Haemophagocytic Lymphohistiocytosis

Summary: the purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis. the new drug can be administered as the first-line therapy, to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the current standard of care. administration will be on top of a glucocorticosteroid, which is usually part of the current recommended treatment.

the purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis. the new drug can be administered as the first-line therapy, to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the current standard of care. administration will be on top of a glucocorticosteroid, which is usually part of the current recommended treatment. all participants in the ni-0501-04 study (nct01818492) were invited to participate in the long-term follow-up study ni-0501-05 (nct02069899). for the primary completion date, mentioned here, we refer to the ni-0501-04 study, even though in accordance with the ni-0501-04 study objectives, namely the assessment of long-term efficacy and safety endpoints, the study analyses also included data collected in the long-term follow-up study ni-0501-05. hence these data are reported together. study ni-0501-05 accepts patients from ni-0501-04 and ni-0501-06. data collection for the patients from ni-0501-04 is completed. the primary efficacy and safety analyses are based on the regulatory cut-off date of 20 july 2017. refer to the publication in n engl j med 2020 may 7; 382 (19):1811-1822. follow-on analyses have been conducted on all patients enrolled in the study, i.e. including the patients enrolled after the cut-off date of 20 july 2017. the results reported here refer to the totality of the 45 patients enrolled.

Eligibility criteria:
inclusion criteria: * gender: male and female * age: up to and including 18 years at diagnosis of haemophagocytic lymphohistiocytosis * primary hlh patients * patient (if ≥ 18 years old), or patient's legal representative(s) must have signed informed consent exclusion criteria: * diagnosis of secondary haemophagocytic lymphohistiocytosis consequent to a proven rheumatic or neoplastic disease. * body weight \< 3 kg. * patients treated with biologics within a specific timeframe * active mycobacteria, histoplasma capsulatum, shigella, salmonella, campylobacter and leishmania infections. * presence of malignancy. * concomitant disease or malformation severely affecting the cardiovascular, pulmonary, liver or renal function

Keywords: emapalumab
development of delirium in patients undergoing open-heart surgery

Conditions: Open-Heart Surgery

Summary: malnutrition is a prevalent issue among patients undergoing cardiac surgery. this can lead to delirium risk factors, including postoperative functional and cognitive impairment. assessing the patient's nutritional status before open-heart surgery may decrease the incidence of delirium and the psychological and physiological problems associated with it. the objective of this study was to examine the relationship between nutritional status and the incidence of postoperative delirium in patients who have undergone open-heart surgery.

upon examining the literature, it was found that the incidence of delirium after open heart surgery ranged from 3% to 70% (tomakin et al., 2020). postoperative delirium has numerous risk factors, including predisposing and accelerating factors. predisposing risk factors comprise malnutrition and electrolyte imbalance, cognitive impairment, depression, and other psychiatric disorders such as dementia (velayati et al., 2019; wilson et al., 2020). this study aims to investigate the relationship between the nutritional status of patients undergoing open heart surgery and the development of postoperative delirium. the study will be conducted in the cardiovascular surgery intensive care unit of bursa uludag university health application and research centre hospital between september 2023 and february 2024. data will be collected using the personal information form, nutritional risk screening score 2002 (nrs-2002), delirium risk assessment form, visual analogue scale for pain levels, richmond agitation sedation scale, glasgow coma scale, and confusion assessment scale in intensive care unit.

Eligibility criteria:
inclusion criteria: * over 18 years old * having undergone open heart surgery * no mental deficiency and visual and hearing impairment * no psychiatric diagnosis and no medication for this purpose * participants' acceptance to participate in the research * the patient is not in coma (rass score between -3 and +4, gcs score of 10 and above) exclusion criteria: * open heart surgery under emergency conditions * diagnosed with delirium, dementia, psychiatric illness before surgery * alcohol and drug addiction * dying in the intensive care unit within 24 hours

Keywords: delirium malnutrition open-heart surgery
evaluation the growth factors(igf-1,igfbp-3and hgh)in patients with chronic liver disease

Conditions: Hepatitis; Liver Cirrhosis; Hepatocellular Carcinoma

Summary: background the insulin-like growth factor system (igfs) plays an important role in cell growth and differentiation. nevertheless, the roles played by insulin-like growth factor-1 (igf-1), insulin-like growth factor binding protein-3 (igfbp-3) and human growth hormone (hgh) in the progression of chronic liver disease remain to be elucidated and investigated. methods the subjects in the present study included 60 healthy controls, 30 hepatitis patients, 60 liver cirrhosis patients and 60 untreated hepatocellular carcinoma patients. blood was drawn by venipuncture into venoject tubes. to find the possible correlations between liver damage and igfs, serum igf-1, gh, igfbp-3 concentration and related biochemical parameters were measured. we used immunoradiometric assay to determine the levels of igf-1, hgh and igfbp-3 in serum.

healthy controls:one blood sample (7.5 cc) hepatitis: three blood samples, at admission, at 3rd and 7-10th day of admission liver cirrhosis: two blood samples, at 1-2 years interval (7.5 cc/each session) hepatocellular carcinoma: three blood samples, before, 1 day after and at the 7th day of transcatheter arterial chembolizatiom

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hepatocellular carcinoma * must be primary hepatocellular carcinoma and untreament exclusion criteria: * treatment hepatocellular carcinoma

Keywords: gh,igf-1, igfbp-3